-

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX)

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Repare Therapeutics Inc. (“Repare” or the “Company”) (NASDAQ: RPTX). The investigation concerns whether Repare and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.

[Click here to learn more about the investigation]

On January 25, 2024, Repare revealed a $40 million milestone payment from its collaboration with Roche for the development and commercialization of camonsertib, an ATR inhibitor. On February 12, 2024, Repare issued a press release “announc[ing] . . . that it will regain global development and commercialization rights to camonsertib…following termination of its collaboration agreement with Roche.” According to the press release, “Roche notified Repare that, effective May 7, 2024, it is terminating its worldwide license and collaboration agreement for the development and commercialization of camonsertib following a review of Roche’s pipeline and evolving external factors.” On this news, the price of Repare shares declined by $1.31 per share, or approximately 15.58%, from $8.41 per share on February 12, 2024 to close at $7.10 on February 13, 2024.

If you purchased or otherwise acquired Repare securities, have information, or would like to learn more about this investigation, contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this CONTACT FORM, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

Kirby McInerney LLP

NASDAQ:RPTX

Release Versions
$Cashtags

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

More News From Kirby McInerney LLP

KLAR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Klarna Group plc Investors

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Klarna Group plc (“Klarna” or the “Company”) (NYSE:KLAR) securities during the period of September 7, 2025 through December 22, 2025, inclusive (“the Class Period”). If you suffered a loss on your Klarna investments, you have until February 20, 2026 to request lead plaintiff appointment. For more information: [CONTACT THE FIRM IF YOU SUFFERED A...

SLM ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of SLM Corporation a/k/a Sallie Mae Investors

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired SLM Corporation a/k/a Sallie Mae (“SLM” or the “Company”) (NASDAQ:SLM) securities during the period of July 25, 2025 through August 14, 2025, inclusive (“the Class Period”). If you suffered a loss on your SLM investments, you have until February 17, 2026 to request lead plaintiff appointment. For more information: [CONTACT THE FIRM IF YOU SUFFER...

FFIV ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of F5, Inc. Investors

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired F5, Inc. (“F5” or the “Company”) (NASDAQ:FFIV) securities during the period of October 28, 2024 through October 27, 2025, inclusive (“the Class Period”). If you suffered a loss on your F5 investments, you have until February 17, 2026 to request lead plaintiff appointment. For more information: [CONTACT THE FIRM IF YOU SUFFERED A LOSS] What Is Th...
Back to Newsroom